Expertise in
7
conditions

Dr. Jason J. Lukas

Oncology
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Expertise in
7
conditions
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 

Overview

Jason Lukas is an Oncologist practicing medicine in Seattle, Washington.

Dr. Lukas is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Multiple Myeloma, and Paget Disease of the Breast.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 6 clinical trials. Dr. Lukas is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in WA

Hospital Affiliations

University Of Washington Medical Ctr
Yakima Valley Memorial
Overlake Hospital Medical Center & Clinics
Swedish Issaquah

Languages Spoken

English
Farsi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Rachel Loschiavo Pa-C
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
Enrollment Status: Completed
Publish Date: March 27, 2026
Intervention Type: Drug, Biological
Study Drugs: SV-BR-1-GM, INCMGA00012, Low Dose Cyclophosphamide, Interferon Inoculation, Epacadosta
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug
Study Drugs: Panobinostat Capsules, Bortezomib Injection, Dexamethasone Tablets
Study Phase: Phase 2
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Biological, Drug
Study Drugs: NeuVax vaccine, Trastuzumab, GM-CSF
Study Phase: Phase 2
A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients
A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients
Enrollment Status: Completed
Publish Date: January 29, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Enrollment Status: Terminated
Publish Date: June 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

3 Total Publications

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
Journal: Clinical immunology (Orlando, Fla.)
Published: October 15, 2020
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Castilian, Hindi, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Ajay Gopal is an Oncologist practicing medicine in Seattle, Washington. Dr. Gopal is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Classical Hodgkin Lymphoma. Dr. Gopal is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Swedish Cardiovascular RSRCH

1221 Madison St Ste 1020, 
Seattle, WA 
 (1.7 miles away)
206-215-2658
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Pagel is an Oncologist practicing medicine in Seattle, Washington. Dr. Pagel is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Leukemia, and Bone Marrow Aspiration. Dr. Pagel is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Uw Division Of Hematology And Oncology

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sara Hurvitz is an Oncologist practicing medicine in Seattle, Washington. Dr. Hurvitz is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Metastatic Brain Tumor, Inflammatory Breast Cancer, and Bone Marrow Aspiration. Dr. Hurvitz is currently accepting new patients.

Frequently Asked Questions about Dr. Jason J. Lukas

How do I make an appointment with Dr. Jason J. Lukas?

You can book an appointment with Dr. Jason J. Lukas by calling their office at 206-228-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jason J. Lukas a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jason J. Lukas is classified as an Advanced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jason J. Lukas specialize in?

While Dr. Jason J. Lukas is a Oncology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jason J. Lukas participate in research or clinical trials?

Yes. Dr. Jason J. Lukas has published 3 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Jason J. Lukas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jason J. Lukas accept my insurance?

Dr. Jason J. Lukas accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 206-228-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lukas's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 57 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile